MRKR Marker Therapeutics Inc
Price (delayed)
$1.18
Market cap
$10.53M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.1
Enterprise value
$1.53M
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy
Highlights
MRKR's revenue has surged by 79% year-on-year and by 45% since the previous quarter
Marker Therapeutics's gross profit has surged by 79% YoY and by 45% QoQ
The EPS is up by 7% since the previous quarter but it is down by 2.8% year-on-year
MRKR's net income is up by 6% since the previous quarter but it is down by 4.4% year-on-year
Marker Therapeutics's equity has plunged by 55% YoY and by 23% from the previous quarter
Marker Therapeutics's quick ratio has plunged by 55% YoY and by 46% from the previous quarter
Key stats
What are the main financial stats of MRKR
Market
Valuations
Earnings
Shares outstanding
8.92M
Market cap
$10.53M
Enterprise value
$1.53M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.41
Price to sales (P/S)
1.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.28
Revenue
$5.4M
Gross profit
$5.4M
Operating income
-$10.19M
Net income
-$9.7M
EBIT
-$9.69M
EBITDA
-$9.69M
Free cash flow
-$8.57M
Per share
Balance sheet
Liquidity
EPS
-$1.1
EPS diluted
-$1.1
Free cash flow per share
-$0.96
Book value per share
$0.83
Revenue per share
$0.6
TBVPS
$1.22
Total assets
$10.91M
Total liabilities
$3.46M
Debt
$0
Equity
$7.45M
Working capital
$7.45M
Debt to equity
0
Current ratio
3.15
Quick ratio
2.82
Net debt/EBITDA
0.93
Margins
Efficiency
Dividend
EBITDA margin
-179.6%
Gross margin
100%
Net margin
-179.7%
Operating margin
-188.9%
Return on assets
-72.1%
Return on equity
-90.2%
Return on invested capital
N/A
Return on capital employed
-130.1%
Return on sales
-179.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRKR stock price
How has the Marker Therapeutics stock price performed over time
Intraday
-15.71%
1 week
-26.71%
1 month
-30.59%
1 year
-72.75%
YTD
-62.06%
QTD
-62.06%
Financial performance
How have Marker Therapeutics's revenue and profit performed over time
Revenue
$5.4M
Gross profit
$5.4M
Operating income
-$10.19M
Net income
-$9.7M
Gross margin
100%
Net margin
-179.7%
MRKR's revenue has surged by 79% year-on-year and by 45% since the previous quarter
Marker Therapeutics's gross profit has surged by 79% YoY and by 45% QoQ
MRKR's operating margin has surged by 61% year-on-year and by 36% since the previous quarter
The company's net margin rose by 42% YoY and by 35% QoQ
Growth
What is Marker Therapeutics's growth rate over time
Valuation
What is Marker Therapeutics stock price valuation
P/E
N/A
P/B
1.41
P/S
1.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.28
The EPS is up by 7% since the previous quarter but it is down by 2.8% year-on-year
The P/B is 63% below the last 4 quarters average of 3.8 and 39% below the 5-year quarterly average of 2.3
Marker Therapeutics's equity has plunged by 55% YoY and by 23% from the previous quarter
MRKR's P/S is 97% below its 5-year quarterly average of 72.8 and 82% below its last 4 quarters average of 11.0
MRKR's revenue has surged by 79% year-on-year and by 45% since the previous quarter
Efficiency
How efficient is Marker Therapeutics business performance
The ROA has plunged by 101% YoY and by 8% from the previous quarter
The ROE has dropped by 73% year-on-year and by 14% since the previous quarter
The ROS is up by 42% year-on-year and by 35% since the previous quarter
Dividends
What is MRKR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRKR.
Financial health
How did Marker Therapeutics financials performed over time
MRKR's total liabilities has surged by 75% since the previous quarter and by 25% year-on-year
Marker Therapeutics's quick ratio has plunged by 55% YoY and by 46% from the previous quarter
The company's debt is 100% lower than its equity
Marker Therapeutics's equity has plunged by 55% YoY and by 23% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.